曲匹地尔与阿司匹林对糖尿病小鼠血小板活性影响的比较

发布时间：2018-07-07 16:20

  本文选题：曲匹地尔 + 阿司匹林　； 参考：《山东医药》2017年46期

【摘要】：目的探讨曲匹地尔对糖尿病小鼠血液中血小板活性的影响及其与阿司匹林相比的效果。方法选择100只健康小鼠,10只为非模型对照组,90只通过腹腔注射四氧嘧啶建立糖尿病模型。取造模成功的60只小鼠,随机分为生理盐水组、阿司匹林组和曲匹地尔组各20只,分别给予生理盐水10 m L、曲匹地尔和阿司匹林25 mg/kg10 m L灌胃,1次/d,连续3 d。3 d后,生理盐水组、阿司匹林组和曲匹地尔组于灌胃后90、120和150 min时尾静脉血取血,同法取非模型对照组尾静脉血。制备富血小板血浆(PRP)及乏血小板血浆(PPP),用比浊法进行血小板聚集性测定,记录血小板聚集率,计算血小板抑制率。结果生理盐水组血小板聚集率高于非模型对照组,曲匹地尔组、阿司匹林组血小板聚集率均低于生理盐水组(P均0.01)。曲匹地尔组、阿司匹林组血小板抑制率均高于生理盐水组,曲匹地尔组血小板抑制率高于阿司匹林组(P均0.01)。90、120、150 min时曲匹地尔组血小板抑制率均高于阿司匹林组(P均0.01)。结论曲匹地尔与阿司匹林均能抑制糖尿病小鼠的血小板聚集,曲匹地尔抗血小板聚集效果强于阿司匹林,对血小板活化抑制时间更持久。
[Abstract]:Objective to investigate the effect of trapidil on platelet activity in blood of diabetic mice. Methods the diabetic model was established by intraperitoneal injection of alloxan in 90 healthy mice as control group (n = 90). Sixty mice were randomly divided into normal saline group (n = 20), aspirin group (n = 20) and trapidil group (n = 20). They were given normal saline 10 mL, trapidil and aspirin 25 mg/kg10 mL intragastrically for 3 days. Normal saline group, aspirin group and trapidil group were collected blood from caudal vein at 90120 and 150 min after gastric perfusion, and caudal vein blood from non-model control group by the same method. Platelet-rich plasma (PRP) and platelet-deficient plasma (PPP) were prepared, platelet aggregation was measured by turbidimetry, platelet aggregation rate was recorded and platelet inhibition rate was calculated. Results the platelet aggregation rate in normal saline group was higher than that in non-model control group, and the platelet aggregation rate in trapidil group and aspirin group was lower than that in normal saline group (P 0.01). The platelet inhibition rate of trapidil group and aspirin group was higher than that of normal saline group, and the platelet inhibition rate of trapidil group was higher than that of aspirin group at 90120150 min (P 0.01). Conclusion Trapidil and aspirin can inhibit platelet aggregation in diabetic mice.
【作者单位】： 大冶市第四人民医院;湖北理工学院医学院;
【基金】：湖北省肾脏疾病发生与干预重点实验室基金项目(222/222205) 教育部留学生启动资金(46-1) 湖北省重点学科湖北理工学院药学学科资助
【分类号】：R587.1
，

本文编号：2105524